BlackRock Inc. boosted its position in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 95,458.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,733,934 shares of the biotechnology company’s stock after buying an additional 2,731,073 shares during the period. BlackRock Inc. owned approximately 7.80% of Prothena Corporation PLC worth $152,526,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new stake in Prothena Corporation PLC during the first quarter worth approximately $167,000. Stifel Financial Corp purchased a new stake in Prothena Corporation PLC during the first quarter worth approximately $224,000. Karp Capital Management Corp purchased a new stake in Prothena Corporation PLC during the first quarter worth approximately $243,000. OMERS ADMINISTRATION Corp purchased a new stake in Prothena Corporation PLC during the first quarter worth approximately $273,000. Finally, Principal Financial Group Inc. raised its stake in Prothena Corporation PLC by 1.2% in the first quarter. Principal Financial Group Inc. now owns 6,528 shares of the biotechnology company’s stock worth $364,000 after buying an additional 77 shares in the last quarter.
Prothena Corporation PLC (PRTA) traded down 1.16% on Friday, reaching $54.59. 343,889 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $60.67 and its 200 day moving average price is $55.21. The company’s market cap is $2.09 billion. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $69.53.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The business had revenue of $26.81 million during the quarter, compared to analyst estimates of $16.08 million. During the same quarter in the previous year, the firm earned ($1.18) EPS. Prothena Corporation PLC’s revenue was up 7951.1% on a year-over-year basis. On average, equities analysts expect that Prothena Corporation PLC will post ($4.52) EPS for the current fiscal year.
A number of equities research analysts have recently commented on PRTA shares. Zacks Investment Research raised shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research note on Friday, August 11th. BidaskClub lowered shares of Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC started coverage on shares of Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 target price on the stock. Oppenheimer Holdings, Inc. set a $70.00 target price on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a research note on Thursday, May 11th. Finally, BTIG Research started coverage on shares of Prothena Corporation PLC in a research note on Friday, May 19th. They set a “buy” rating and a $80.00 target price on the stock. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Prothena Corporation PLC presently has an average rating of “Buy” and an average target price of $77.58.
In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now owns 6,345 shares of the company’s stock, valued at approximately $368,707.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by insiders.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.